248 related articles for article (PubMed ID: 35382560)
21. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
22. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
Tarantino P; Barroso-Sousa R; Garrido-Castro AC; McAllister SS; Guerriero JL; Mittendorf E; Curigliano G; Tolaney SM
Expert Rev Anticancer Ther; 2022 Feb; 22(2):141-153. PubMed ID: 34919490
[TBL] [Abstract][Full Text] [Related]
23. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
24. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Li S; Zhang C; Pang G; Wang P
Front Immunol; 2020; 11():603157. PubMed ID: 33178229
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.
Pabst L; Lopes S; Bertrand B; Creusot Q; Kotovskaya M; Pencreach E; Beau-Faller M; Mascaux C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108738
[TBL] [Abstract][Full Text] [Related]
26. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Kang BW; Chau I
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817133
[TBL] [Abstract][Full Text] [Related]
27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
28. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
Shklovskaya E; Rizos H
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
30. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis.
Frega G; Cossio FP; Banales JM; Cardinale V; Macias RIR; Braconi C; Lamarca A
Cells; 2023 Aug; 12(16):. PubMed ID: 37626908
[TBL] [Abstract][Full Text] [Related]
31. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
32. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.
Chen L; Jiang X; Li Y; Zhang Q; Li Q; Zhang X; Zhang M; Yu Q; Gao D
Clin Immunol; 2022 Apr; 237():108962. PubMed ID: 35227870
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.
Perrino M; De Vincenzo F; Cordua N; Borea F; Aliprandi M; Santoro A; Zucali PA
Front Immunol; 2023; 14():1121557. PubMed ID: 36776840
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G; Wang Y; Zhang H; She X; Yang J
Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
[TBL] [Abstract][Full Text] [Related]
35. Immune Oncology Biomarkers in Lung Cancer: an Overview.
Travert C; Barlesi F; Greillier L; Tomasini P
Curr Oncol Rep; 2020 Aug; 22(11):107. PubMed ID: 32803433
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Wang G; Chai Q; Xiao Y; Peng W; Teng M; Wang J; Lin H; Su X; Wu L
Front Immunol; 2020; 11():607416. PubMed ID: 33584678
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
Ricci AD; Rizzo A; Brandi G
Cancer Control; 2020; 27(3):1073274820948047. PubMed ID: 32806956
[TBL] [Abstract][Full Text] [Related]
39. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
